ANEB

Anebulo Pharmaceuticals, Inc. ANEB

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q4 2025
$91.57M total
22NW, LP
$84.76M0.0%
Nantahala Capital Management, LLC
$3.07M0.0%
MANGROVE PARTNERS IM, LLC
$2.55M0.0%
VANGUARD GROUP INC
$440.2K+42.2%
MORGAN STANLEY
$403.4K0.0%
GEODE CAPITAL MANAGEMENT, LLC
$162.5K-7.7%
Rangeley Capital, LLC
$50.5K+150.0%
RENAISSANCE TECHNOLOGIES LLC
$25.3K-11.9%
CITADEL ADVISORS LLC
$24.5KNew
BlackRock, Inc.
$24.0K-1.1%
NORTHERN TRUST CORP
$22.2K-9.8%
Ikarian Capital, LLC
$17.9K-88.8%
STATE STREET CORP
$12.9K0.0%
Tower Research Capital LLC (TRC)
$3.3K+84.6%
UBS Group AG
$2.4K+960.9%
JPMORGAN CHASE & CO
$2.3K-47.3%
BANK OF AMERICA CORP /DE/
$386-57.1%
ROYAL BANK OF CANADA
$0New
FNY Investment Advisers, LLC
$0+5.3%
See all 19 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ANEB

Earnings Per Share

13fpro.ai/company/ANEB

Loading ratio trend…

About Anebulo Pharmaceuticals, Inc. (ANEB): stock profile, AI score and financials

Anebulo Pharmaceuticals, Inc. (ANEB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ANEB is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. ANEB trades on the Nasdaq exchange and files with the SEC under CIK 1815974. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANEB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Anebulo Pharmaceuticals, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1815974 →